Renal Cell Carcinoma Treatment Guidelines

Introduction to Renal Cell Carcinoma

The American Urological Association recommends that treatment for renal cell carcinoma should be guided by tumor stage, with surgical options for localized disease and systemic therapy for advanced disease, prioritizing approaches that maximize survival and quality of life 1, 2

The TNM staging system is used for renal cell carcinoma (RCC) classification, which includes T1: Tumor ≤7 cm, limited to kidney, T2: Tumor >7.0 cm, limited to kidney, T3: Tumor extends to major veins or perinephric tissues but not beyond Gerota fascia, and T4: Tumor invades beyond Gerota fascia 1, 2, 3
The National Comprehensive Cancer Network recommends the use of the TNM staging system to guide treatment decisions for renal cell carcinoma 2

For tumors <7 cm (T1), the European Association of Urology recommends partial nephrectomy as the first choice, which preserves renal function with equivalent oncological outcomes to radical nephrectomy 1, 4
The 5-year survival rate for stage I renal cell carcinoma is approximately 95% 1, 5
For tumors >7 cm (T2), the American Urological Association recommends radical nephrectomy as the preferred option, with a 5-year survival rate of approximately 88% 1, 4, 5

For T3-T4 tumors, the National Comprehensive Cancer Network recommends radical nephrectomy plus adrenalectomy, with a 5-year survival rate of approximately 59% 1, 4, 5
The European Association of Urology recommends lymph node dissection for clinically enlarged lymph nodes 1, 4

The American Society of Clinical Oncology recommends cytoreductive nephrectomy in patients with good performance status, with a 5-year survival rate for stage IV renal cell carcinoma of approximately 20% 1, 2, 4, 6
For good and intermediate-risk patients, the European Association of Urology recommends VEGF-targeted agents and tyrosine kinase inhibitors (TKIs) as first-line therapy, including sunitinib, bevacizumab plus interferon-α, and tivozanib 1, 2, 4, 6
For intermediate and poor-risk patients, the National Comprehensive Cancer Network recommends nivolumab plus ipilimumab as first-line therapy, with cabozantinib and temsirolimus as alternative options 2, 4, 6

The Memorial Sloan Kettering Cancer Center (MSKCC) risk model divides patients into three groups based on risk factors, including low Karnofsky performance status, elevated lactate dehydrogenase, low serum hemoglobin, elevated corrected serum calcium, and time from diagnosis to therapy <1 year 2, 7
The 5-year survival rate for metastatic renal cell carcinoma has improved significantly with modern targeted therapies, from ~15 months before 2004 to ~30 months with newer therapies 1, 5